Top Markets
#1 Resolv wstUSR Resolv wstUSR +114.61%
#2 Luxxcoin Luxxcoin +45.15%
#3 ResearchCoin ResearchCoin +21.62%
#4 Reactive Network Reactive Network +21.45%
#5 Layer3 Layer3 +19.67%
#6 Orderly Network Orderly Network +16.55%
#7 Aria.AI Aria.AI +12.61%
#8 Bitgert Bitgert +11.76%
#9 Lisk Bridged wstETH (Lisk) Lisk Bridged wstETH (Lisk) +9.32%
#10 KAITO KAITO +9.04%
Coin of the day
Resolv wstUSR Resolv wstUSR
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
CSL Limited CSL Limited

CSL Limited

CSL
Classifica tra le azioni #432
CSL Limited researches, develops, manufactures, markets, and distributes... CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
Prezzo delle azioni
$99.32
Capitalizzazione di mercato
$48.20B
Variazione (1 giorno)
0.98%
Variazione (1 anno)
-32.14%
Paese
AU
Scambia CSL Limited (CSL)

Categoria

Healthcare
Utile per CSL Limited (CSL)
Utile nel Dec 2025 TTM: $1.61B
Secondo gli ultimi rapporti finanziari di CSL Limited, gli utili attuali della società sono $1.61B. Nel 2024, la società ha registrato un utile di $3.38B, un aumento rispetto a agli utili del 2023, che erano di $2.66B. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di CSL Limited dal 2000 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
2026 (TTM) $1.61B -56.65%
2025 $3.72B 10.34%
2024 $3.38B 26.74%
2023 $2.66B -4.19%
2022 $2.78B -6.80%
2021 $2.98B 15.92%
2020 $2.57B 9.89%
2019 $2.34B 2.63%
2018 $2.28B 35.00%
2017 $1.69B 8.61%
2016 $1.56B -9.22%
2015 $1.71B 6.84%
2014 $1.60B 19.64%
2013 $1.34B 5.36%
2012 $1.27B -7.31%
2011 $1.37B 38.29%
2010 $992.87M 11.00%
2009 $894.45M 2.37%
2008 $873.74M 56.73%
2007 $557.47M 493.43%
2006 $93.94M -74.77%
2005 $372.39M 201.20%
2004 $123.64M 168.99%
2003 $45.96M -7.38%
2002 $49.63M -8.38%
2001 $54.17M 88.04%
2000 $28.81M 0.00%
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$20.51B 1,170.24%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$4.64B 187.63%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.23B 224.03%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B 32.42%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.45B -10.11%
NL